ArticleCancer medicine2026
Transgelin Expression in Activated Cancer-Associated Fibroblasts Regulates Stromal Contractility and Promotes Colon Cancer Progression.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Transgelin is an actin-binding protein that promotes cancer progression via activation of cancer-associated fibroblasts and has been identified as a prognostic marker. However, its distribution and functional role in colon cancer remain unclear. In this study, we aimed to elucidate the mechanistic role of transgelin in colon cancer progression by focusing on its functional impact in cancer-associated fibroblasts. Tissue microarrays from 359 human colon cancer tissues were investigated to elucidate the clinical importance of transgelin expression in cancer stroma. We focused on transgelin in fibroblasts and investigated its functional role in stromal activation using in vitro knockdown experiments and in vivo co-transplantation models. Primary cultures of human colon fibroblasts were evaluated for their biological function. Our data showed that transgelin expression is predominant in activated cancer-associated fibroblasts in colon cancer tissues. Stimulation by cancer-cell-conditioned medium (CM) significantly upregulated transgelin, ACTA2, COL1A1, and TNC expression in colonic fibroblasts. Additionally, transgelin knockdown (KD) in fibroblasts did not influence the upregulation except for transgelin itself. Transgelin KD in fibroblasts did not result in drastic alterations in gene expression profiles. Transgelin KD suppressed collagen gel contractility. Furthermore, co-transplantation experiments of cancer cells and colonic fibroblasts into immunodeficient mice revealed that transgelin KD inhibited tumor growth in fibroblasts. In conclusion, stromal transgelin expression in colon cancer strongly correlated with distant metastasis and served as a prognostic factor for colon cancer. Mechanistically, transgelin in cancer-associated fibroblasts promotes tumor growth by regulating stromal contractility, suggesting transgelin as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.